These outstanding results call for discussion of the clinical implications, and in-depth studies of the mechanisms of action of SGLT2 inhibitors.doi:10.1038/nrcardio.2016.35Raz, ItamarCahn, AvivitNat Rev CardiolNature Reviews CardiologyRaz I, Cahn A. Heart failure: SGLT2 inhibitors and heart ...
[4]O'Meara E, McDonald M,Chan M,et al.CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors,ARNl in HFpEF, and Tafamidis in Amyloidosis[]]Can J Cardiol,2020,36(2):159-169. [5]廖梦阳...
Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of symptoms and functional limitations, and have a poor quality of life. By targeting cardiometabolic abmormalities, sodium glucose cotransporter 2 (SGLT2) inhibitors may improve these impairments. In this multic...
[6] Talha K M, Anker S D, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence[J]. International Journal of Heart Failure, 2023, 5(2): 82. [7] McDonagh T A, Metra M, Adamo M, et al. 2021 ESC G...
Both heart failure and diuretic or SGLT2 inhibitor use increase fall risk in older adults. Diuretics and SGLT2 inhibitors not only have various fall-related adverse effects, which partly overlap (e.g. tendency to cause hypotension), but also differ: compared to SGLT2is, diuretics display more...
SGLT-2 inhibitors in heart failure: a new therapeutic avenueDapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction....
Heart failure with reduced ejection fraction prognosis-modifying pharmacological therapy is currently based on the triple combination of angiotensin-converting enzyme inhibitors (ACEi)/angiotensin-II receptor blockers (ARB)/angiotensin receptor-neprilysin inhibitor (ARNi), with a beta-blocker (BB), and a...
Investigating SGLT2 Inhibitors in Heart Failure Heart failure with preserved ejection fraction (HFpEF) is a chronic disease that is increasing in prevalence and contributes to the overall incidence of he... L Mann,A Smith - 《U.s.pharmacist》 被引量: 0发表: 2023年 加载更多来源...
The results of a review, published in Cureus, show that the medications reduced the risk of HF. Investigators found that sodium-glucose contrasporter-2 (SGLT2) inhibitors demonstrated effectiveness for the primary and secondary prevention of heart failure (HF) across a broad range of care ...
)SGLT2inhibitorsandmechanismsofcardiovascularbenefit:astat e-of-the-artreview.Diabetologia.61(10):2108-2117目录达格列净突破性排糖,通过 三重机制,实现心脏获益达格列净助力心血管全病程血糖管理,获得权威指南更新推荐达格列净在更广泛早期人群实现心获益,助力心血管全病程血 ...